CuraVac 

Therapeutic Vaccines for Autoimmune Diseases

OWNER

Stephane Huberty (See Profile)


Sector

Immunology

Stage

Development, market readiness, clinical trial

Country

Belgique


Revolutionary treatment platform to induce long-lasting improvement to patients suffering of autoimmune diseases.

Excellent safety profile and indication of long-term efficacy in a phase 1b trial on patients with myasthenia gravis.

Designated Orphan Drug Ready for phase 2b demonstration of efficacy in Myasthenia Gravis.

Status

Approved

IP Type

Patent

Time

20 years

Countries

Australia
Austria
Belgium
Canada
China
Denmark
France
Germany
Israel
Italy
Japan
Netherlands
South Korea
Spain
Switzerland
USA
United Kingdom

Coverage

4 patents:
2 for the Therapeutic Vaccine for Myasthenia Gravis, 1 filed in 2007 and 1 filed in 2021
1 for a production method of the CRM197 carrier protein
1 for the conjugaison method of peptides to carrier proteins

Know more of this patent

View more

This information is confidential, do not share or copy.

You can visit their website or

Download the Pitch Deck
Other files:

Patients' Survey

Under evaluation at least till: 18th of June 2023

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar